23 hours Ago By Defense World Staff
Renaissance Technologies LLC lifted its holdings in Lineage Cell Therapeutics, Inc. ( NYSEAMERICAN:LCTX – Free Report ) by 1,058.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).
The fund owned 2,283,072 shares of the company’s stock after purchasing an additional 2,085,972 shares during the period. Renaissance Technologies LLC owned about 1.04% of Lineage Cell Therapeutics worth $1,147,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Fort Sheridan Advisors LLC boosted its position in shares of Lineage Cell Therapeutics by 71.5% in the 4th quarter.
Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock valued at $28,000 after purchasing an additional 23,000 shares during the period. HighTower Advisors LLC boosted its holdings in shares of Lineage Cell Therapeutics by 49.5% in the fourth quarter.
HighTower Advisors LLC now owns 57,706 shares of the company’s stock worth $29,000 after buying an additional 19,100 shares during the period. Atria Wealth Solutions Inc. purchased a new position in shares of Lineage Cell Therapeutics in the fourth quarter worth approximately $29,000.
SG Americas Securities LLC raised its holdings in shares of Lineage Cell Therapeutics by 35.5% during the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock valued at $35,000 after acquiring an additional 18,053 shares during the period.
Finally, Wells Fargo & Company MN lifted its position in shares of Lineage Cell Therapeutics by 33.0% in the 4th quarter. Wells Fargo & Company MN now owns 94,894 shares of the company’s stock valued at $48,000 after acquiring an additional 23,527 shares in the last quarter.
62.47% of the stock is currently owned by institutional investors. Wall Street Analysts Forecast Growth LCTX has been the topic of several recent analyst reports.
HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. B.
Riley decreased their price objective on Lineage Cell Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, March 14th.
Maxim Group dropped their target price on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, January 10th.
Finally, D. Boral Capital restated a “buy” rating and set a $2.00 price target on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th.
Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Lineage Cell Therapeutics currently has an average rating of “Buy” and an average price target of $4.20.
Lineage Cell Therapeutics Trading Up 2.4 % Lineage Cell Therapeutics stock opened at $0.47 on Wednesday.
The company has a market capitalization of $103.82 million, a P/E ratio of -3.93 and a beta of 1.
21. Lineage Cell Therapeutics, Inc. has a 1-year low of $0.
37 and a 1-year high of $1.40. The firm’s fifty day simple moving average is $0.
50 and its 200-day simple moving average is $0.65. About Lineage Cell Therapeutics ( Free Report ) Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally.
The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. Recommended Stories Five stocks we like better than Lineage Cell Therapeutics The Basics of Support and Resistance Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Why Special Dividends Can be a Delightful Surprise for Income Investors Coca-Cola Company Stock Can Bubble to New Highs This Year 3 Tickers Leading a Meme Stock Revival 3 Stocks Lifting 2025 Guidance Despite Market Jitters Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
